Table 3 Ongoing clinical trials of ASP8273
From: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Phase | Study population | NCT no. |
|---|---|---|
Phase I | NSCLC patients who have EGFR mutations and received prior treatment with EGFR TKI | 02113813 |
Phase I/II | NSCLC with EGFR mutation and had progressive disease after previous treatment with EGFR TKIs | 02192697 |
Phase II | NSCLC with EGFR mutation and TKI naïve patients | 02500927 |
Phase III | Stage IIIB/IV NSCLC with EGFR mutations | 02588261 |